Healthcare

Market Dynamics, Policies and Strategies in Europe

Edited by
Mario Glowik, Sławomir Smyczek
Contents

Preface — v

Justyna Matysiewicz
1 Introduction to the European Healthcare Market — 1
1.1 Introduction — 1
1.2 Concept of the healthcare system — 1
1.3 Healthcare systems in the EU — 3
1.4 Healthcare expenditure — 7
1.5 Private health insurance in the EU — 9
1.6 EU healthcare systems: the patient perspective — 12
References — 14

Jagoda Gola
2 Investment Attractiveness of the Healthcare Markets in Europe — 17
2.1 Introduction — 17
2.2 Investment attractiveness – theoretical attitude — 17
2.3 Macro-level factors influencing medical market attractiveness — 19
2.4 Micro-level factors influencing medical market attractiveness — 27
2.5 Available market attractiveness measures — 35
2.6 Forecasts – potential areas of investment — 37
Conclusions — 39
References — 40

Artur Turek and Aleksander Owczarek
3 Consumption and Consumer Behavior in the European Healthcare Market — 45
3.1 Introduction — 45
3.2 Medication reimbursement systems — 47
3.3 Changes to the pharmaceutical market in the period 2008 to 2012 — 49
3.4 Materials and methods — 50
3.5 Results — 51
3.6 Discussion — 60
Conclusions — 66
References — 67
Marta Grybš
7 Integrated Marketing Communication in the European Healthcare Market — 119
  7.1 Introduction — 119
  7.2 Integrated marketing communication – notion and characteristics — 120
  7.3 Healthcare marketing communication — 123
  7.4 European healthcare marketing communication — 128
  7.4.1 Healthcare marketing communication in Germany — 128
  7.4.2 Healthcare marketing communication in the United Kingdom — 131
  7.4.3 Healthcare marketing communication in Sweden — 133
  7.4.4 Healthcare marketing communication in Belgium — 135
  7.4.5 Healthcare marketing communication in Poland — 137
Conclusions — 140
References — 141

Beatrix Dietz and Andreas Zaby
8 Strategic Decisions under the EU Regulatory Framework for Orphan Drugs — 145
  8.1 Introduction — 145
  8.2 Background — 145
  8.2.1 Current Situation and the EU Regulatory Framework for Orphan Drugs — 145
  8.2.2 Analytical Approach — 147
  8.3 Market Dynamics and Strategic Decisions in the Orphan Drug Segment — 148
  8.3.1 Designation and Holder of Marketing Authorization — 148
  8.3.2 Changes from Designation to Marketing Authorization — 150
  8.3.3 Role of Service Providers — 151
  8.3.4 Strategic Company Decisions — 152
  8.4 Summary and Recommendations — 154
References — 155

Agnieszka Marie
9 Healthcare Business Performance – Control Mechanisms — 157
  9.1 Introduction — 157
  9.2 Business performance control mechanisms — 158
  9.3 Measures of performance in the healthcare system — 158
  9.4 Balanced scorecard for healthcare organizations — 161
  9.4.1 Germany – emergency department of the hospital in Friedrichshain — 163
  9.4.2 United Kingdom – Ashford and St. Peter’s hospitals — 166